Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Other Disease Areas
Filter     Order     Display # 
Date Item Title Hits
15 Mar 2010 AXIRON NDA currently under review by U.S. FDA for the treatment of testosterone deficiency in men 4
15 Mar 2010 Inspire Announces Results From AZASITE® Phase 2 Blepharitis Trials and Plans to Continue Clinical Development in Anterior and Posterior Blepharitis 41
12 Mar 2010 Progenics to Advance Oral Methylnaltrexone into Late Stage Clinical Development 6
09 Mar 2010 FDA Advisory Committee Recommends Approval of InterMune's Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis 93
03 Mar 2010 Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 7
03 Mar 2010 Rexahn Pharmaceuticals Submits Zoraxel Phase IIb Protocol to FDA 6
03 Mar 2010 NicOx and Bausch + Lomb Announce Worldwide Licensing Agreement for NCX 116 147
02 Mar 2010 Capstone Therapeutics Announces Continuation of AZX100 Phase 2 Clinical Trial in Keloid Scarring 5
02 Mar 2010 Antares Pharma Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of Anturol for the Treatment of Overactive Bladder 8
02 Mar 2010 Lux Biosciences Receives Acceptance of Luveniq MAA Filing from European Medicines Agency 8
02 Mar 2010 InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 9
02 Mar 2010 SHIONOGI ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH QUATRX PHARMACEUTICALS TO MARKET OSPEMIFENE 5
01 Mar 2010 Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007 12
01 Mar 2010 BUILD-3 study with bosentan in idiopathic pulmonary fibrosis does not meet primary endpoint 8
26 Feb 2010 Withdrawn application for approval of additional indication for type 2 diabetic incipient nephropathy for "Micardis®Tablets", Angiotensin II receptor blocker 8
26 Feb 2010 Rockwell Medical Announces Positive Phase IIb Clinical Data 9
24 Feb 2010 Pantec Biosolutions reports successful Phase I for delivery of FSH using P.L.E.A.S.E.® 25
24 Feb 2010 Welichem Begins Patient Enrollment for Phase IIa Trial of WBI-1001 Cream in Patients with Psoriasis 9
18 Feb 2010 VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema 63
12 Feb 2010 3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial 83
10 Feb 2010 Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 14
10 Feb 2010 Nymox Provides Update on Pivotal Phase 3 Trials for BPH Drug 13
10 Feb 2010 Nymox Provides Update on Pivotal Phase 3 Trials for BPH Drug 67
09 Feb 2010 ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 16
09 Feb 2010 Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 16
08 Feb 2010 3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 18
08 Feb 2010 Repros Submits Response to FDA Regarding Androxal® Indication for Treatment of Hypogonadal Men Wishing to Preserve Fertility 14
04 Feb 2010 Isotechnika partner files for approval of voclosporin in US and Europe 32
04 Feb 2010 Paloma Pharmaceuticals Receives Approval to Enter Phase I Clinical Trials 75
03 Feb 2010 Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX(TM) for the Treatment of Dupuytren's Contracture 24
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1500

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

Oncology Market Leaders
Order Now

Subscribe La Merie Biologics